Iqvia initiated with a Buy at Truist on attractive organic growth rate

As previously reported, Truist initiated coverage of Iqvia with a Buy rating and $265 price target. Since merging with IMS Health in 2006, the company has now become a global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, the analyst tells investors in a research note. Iqvia’s CRO, or contract research organization, business is "highly differentiated" given its global infrastructure, late-stage clinical trials focus, and diversified client base, the firm states, adding that it’s breadth of offerings is resulting in strong growth in its backlog as it continues to grow at an attractive organic growth rate.